Head to Head Comparison: Hyperfine (NASDAQ:HYPR) vs. Envoy Medical (NASDAQ:COCH)

Envoy Medical (NASDAQ:COCH) and Hyperfine (NASDAQ:HYPR) are both small-cap medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their earnings, analyst recommendations, dividends, institutional ownership, valuation, risk and profitability.

Volatility and Risk

Envoy Medical has a beta of 2.19, suggesting that its share price is 119% more volatile than the S&P 500. Comparatively, Hyperfine has a beta of 1.07, suggesting that its share price is 7% more volatile than the S&P 500.

Valuation and Earnings

This table compares Envoy Medical and Hyperfine”s gross revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Envoy Medical	$222,000.00	126.99	-$20.80 million	($1.43)	-0.92
Hyperfine	$12.89 million	8.84	-$40.72 million	($0.52)	-2.79

Envoy Medical has higher earnings, but lower revenue than Hyperfine. Hyperfine is trading at a lower price-to-earnings ratio than Envoy Medical, indicating that it is currently the more affordable of the two stocks.

Profitability

This table compares Envoy Medical and Hyperfine’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Envoy Medical	-10,961.26%	N/A	-236.14%
Hyperfine	-364.54%	-84.82%	-69.39%

Institutional and Insider Ownership

8.6% of Envoy Medical shares are held by institutional investors. Comparatively, 15.0% of Hyperfine shares are held by institutional investors. 58.9% of Envoy Medical shares are held by insiders. Comparatively, 31.0% of Hyperfine shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

Analyst Recommendations

This is a summary of recent recommendations and price targets for Envoy Medical and Hyperfine, as provided by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Envoy Medical	0	0	2	0	3.00
Hyperfine	0	1	2	0	2.67

Envoy Medical currently has a consensus price target of $9.25, indicating a potential upside of 606.11%. Hyperfine has a consensus price target of $1.28, indicating a potential downside of 11.49%. Given Envoy Medical’s stronger consensus rating and higher probable upside, research analysts clearly believe Envoy Medical is more favorable than Hyperfine.

Summary

Envoy Medical beats Hyperfine on 8 of the 13 factors compared between the two stocks.

About Envoy Medical

Envoy Medical, Inc., a hearing health company, provides medical technologies for the hearing loss spectrum. Its products include personal sound amplification devices; hearing aids; Esteem fully implanted active middle ear implants; auditory osseointegrated implants; and Acclaim cochlear implants. The company was formerly known as Envoy Medical Corporation and changed its name to Envoy Medical, Inc. in September 2023. Envoy Medical, Inc. was founded in 1995 and is headquartered in White Bear Lake, Minnesota.

About Hyperfine

Hyperfine, Inc., a medical device company, provides magnetic resonance imaging (MRI) products in the United States. The company offers Swoop Portable MR imaging system, which offers portable brain neuroimaging; and support and technical assistance services. It serves ICU, comprehensive, and primary stroke accredited facilities through direct sales and distributors. Hyperfine, Inc. was founded in 2014 and is based in Guilford, Connecticut.